(Q39664082)

13 September 2017

title

Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma (English)

1 reference

13 September 2017

1 reference

Yin-Hsun Feng

1

1 reference

13 September 2017

Cheng-Yao Lin

2

1 reference

13 September 2017

Wen-Tsung Huang

3

1 reference

13 September 2017

Chia-Ling Wu

4

1 reference

13 September 2017

Jui-Lung Fang

5

1 reference

13 September 2017

Chao-Jung Tsao

6

1 reference

13 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20734163

21 June 2024

publication date

24 August 2010

1 reference

full work available at URL

13 September 2017

http://link.springer.com/content/pdf/10.1007/s12032-010-9650-9.pdf

file format

Portable Document Format

1 reference

DOI

https://api.crossref.org/works/10.1007/S12032-010-9650-9

http://link.springer.com/article/10.1007/s12032-010-9650-9/fulltext.html

21 June 2024

1 reference

https://api.crossref.org/works/10.1007/S12032-010-9650-9

http://link.springer.com/content/pdf/10.1007/s12032-010-9650-9

21 June 2024

1 reference

DOI

https://api.crossref.org/works/10.1007/S12032-010-9650-9

21 June 2024

1 reference

13 September 2017

volume

28

1 reference

13 September 2017

issue

4

1 reference

13 September 2017

page(s)

1080-1088

1 reference

Global cancer statistics in the year 2000.

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Treatment modalities for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Evolution of systemic therapy of advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Diabetes mellitus and the risk of primary liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Glucosamine Induces Resistance to Insulin-Like Growth Factor I (IGF-I) and Insulin in Hep G2 Cell Cultures: Biological Significance of IGF-I/Insulin Hybrid Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Insulin can modulate MCF-7 cell response to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Mortality and causes of death in patients with diabetes mellitus in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Excess risk of primary liver cancer in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Dysregulation of growth factor signaling in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9650-9

Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil

21 January 2018

1 reference

12 December 2020

Hepatocellular carcinoma: therapy and prevention

1 reference

12 December 2020

Antidiabetic therapies affect risk of pancreatic cancer

1 reference

12 December 2020

Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis

1 reference

12 December 2020

In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols

1 reference

12 December 2020

Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression

1 reference

12 December 2020

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

12 December 2020

Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma.

1 reference

12 December 2020

Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis

1 reference

12 December 2020

Insulinlike growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers

1 reference

12 December 2020

The blood supply of neoplasms in the liver

1 reference

12 December 2020

Diabetes mellitus in chronic active hepatitis and cirrhosis

1 reference

12 December 2020

Reversal of enhanced pancreatic cancer growth in diabetes by insulin1

1 reference

12 December 2020

Hepatocellular carcinoma in the Asia pacific region

1 reference

12 December 2020

Therapeutic options for the management of type 2 diabetes mellitus

1 reference

12 December 2020

Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma.

1 reference

12 December 2020

Identifiers

DOI

1 reference

13 September 2017

1 reference